Lexaria Bioscience (LEXX) said Wednesday it received approval from the lead clinical site's human research ethics committee to begin dosing in its phase 1b, 12-week chronic study of GLP-1-H24-4 for diabetes and weight loss.
The study will feature five arms testing various DehydraTECH formulations including CBD capsules, semaglutide capsules, semaglutide combined with CBD capsules, Rybelsus tablets as control, and optional tirzepatide capsules, the company said.
Clinical test article manufacturing for all study arms is complete, with a first patient, first dose study milestone slated to be achieved in late December or January 2025, Lexaria said.
The study will take place across seven clinical sites in Australia and is expected to be recognized by the US Food and Drug Administration as a registrational phase 1b study, the company said.
Shares of Lexaria were up 3.9% in recent Wednesday trading.
Price: 2.39, Change: +0.09, Percent Change: +3.91
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。